$-0.19 EPS Expected for Abeona Therapeutics Inc. (ABEO)

April 23, 2018 - By Marguerite Chambers

Abeona Therapeutics Inc. (NASDAQ:ABEO) Logo

Analysts expect Abeona Therapeutics Inc. (NASDAQ:ABEO) to report $-0.19 EPS on May, 21.They anticipate $0.06 EPS change or 46.15 % from last quarter’s $-0.13 EPS. After having $-0.19 EPS previously, Abeona Therapeutics Inc.’s analysts see 0.00 % EPS growth. The stock decreased 4.31% or $0.9 during the last trading session, reaching $20. About 1.51M shares traded or 22.74% up from the average. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 188.66% since April 24, 2017 and is uptrending. It has outperformed by 177.11% the S&P500.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 5 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 14 analyst reports since November 2, 2017 according to SRatingsIntel. The rating was maintained by Jefferies on Tuesday, November 21 with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $3000 target in Friday, April 20 report. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by RBC Capital Markets on Tuesday, January 23. The rating was maintained by H.C. Wainwright on Thursday, February 8 with “Buy”. As per Wednesday, November 22, the company rating was maintained by H.C. Wainwright. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Thursday, January 4 by H.C. Wainwright. On Monday, January 29 the stock rating was maintained by Cantor Fitzgerald with “Buy”. H.C. Wainwright maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Monday, April 2. H.C. Wainwright has “Buy” rating and $3000 target. The firm earned “Buy” rating on Thursday, November 2 by RBC Capital Markets. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by H.C. Wainwright on Thursday, April 12.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $944.54 million. The company's lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.